Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sijmen de Vries M.B.A., M.D. | President, CEO & Executive Director | 1.29M | -- | 1959 |
| Mr. Jeroen Wakkerman | Chief Financial Officer | -- | -- | 1969 |
| Ms. Mireille Sanders M.Sc. | Chief Operations Officer | -- | -- | 1968 |
| Ms. Susanne Embleton | Investor Relations Manager | -- | -- | -- |
| Mr. Ruud Van Outersterp | Chief Ethics & Compliance Officer | -- | -- | 1964 |
| Ms. Ines Bernal | Chief People Officer | -- | -- | -- |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer | -- | -- | 1972 |
| Mr. Stephen Toor | Chief Commercial Officer & GM Americas | -- | -- | 1971 |
| Dr. Alexander Breidenbach M.B.A. | Chief Business Officer | -- | -- | 1964 |
| Dr. Bruno M. L. Giannetti | Consultant | -- | -- | 1952 |
Pharming Group N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 382
Description
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Corporate Governance
Upcoming Events
March 12, 2025 at 6:00 AM UTC - March 17, 2025 at 6:00 AM UTC
Pharming Group N.V. Earnings Date